Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Asston Pharmaceuticals's Revenue for the
six
months ended in Mar. 2026 was ₹100.5 Mil. Asston Pharmaceuticals's average Accounts Receivable for the
six
months ended in Mar. 2026 was ₹350.7 Mil.
Hence, Asston Pharmaceuticals's Receivables Turnover for the
six
months ended in Mar. 2026 was 0.29.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Asston Pharmaceuticals Receivables Turnover Related Terms
Asston Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Asston Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544445 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Asston Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asston Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asston Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Asston Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asston Pharmaceuticals (BOM:544445) has a Receivables Turnover of 0.29 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Asston Pharmaceuticals and its competitors. According to the industry distribution chart, Asston Pharmaceuticals ranks #930 out of 947 companies in the Drug Manufacturers industry, placing it in the top 98.2%.
Is Asston Pharmaceuticals' Receivables Turnover too high?
Asston Pharmaceuticals' current Receivables Turnover is 0.29. The Drug Manufacturers industry median Receivables Turnover is 5.08. Asston Pharmaceuticals' value of 0.29 is 94.3% below this industry median. Based on the distribution chart, Asston Pharmaceuticals ranks #930 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Asston Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Asston Pharmaceuticals ranks #930 out of 947 companies for Receivables Turnover. This places Asston Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.08. Asston Pharmaceuticals' value of 0.29 is 94.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asston Pharmaceuticals's current Receivables Turnover of 0.29 is 94.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Asston Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asston Pharmaceuticals's current Receivables Turnover is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current Receivables Turnover of 0.29. The current Receivables Turnover is 0.29 and 94.3% below the Drug Manufacturers industry median of 5.08. Asston Pharmaceuticals' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current Receivables Turnover is 0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
20GF Score
Get the complete analysis for BOM:544445
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544445 has been successfully added to your 
